Who founded Nitrase Therapeutics?

Nitrase Therapeutics was founded by Irene Griswold-Prenner in 2018.

Who are Nitrase Therapeutics's investors?

Nitrase Therapeutics's investors include Dementia Discovery Fund, Mission Biocapital, Sofinnova Partners, SV Health Investors, AbbVie, Mission Bay Capital.

Nitrase Therapeutics

Founded 2018 · 14 employees on LinkedIn · 6 known investors

Find your way into Nitrase Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Nitrase Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration. Its lead program is an antibody targeting the pathogenic form of alpha-synuclein in Parkinson's disease, with a pipeline aimed at neurodegenerative, cancer, fibrotic, respiratory, and autoimmune diseases.

Biotech Healthtech Longevity

Founders & leadership

Nitrase Therapeutics was founded in 2018 by Irene Griswold-Prenner.

Irene Griswold-Prenner Founder & Chief Executive OfficerGriswold-Prenner holds a PhD in Drug Target and Discovery from the University of Chicago and has prior experience in biotechnology, stem cell research, and neuroscience drug development. She is Founder and CEO of Nitrase Therapeutics, a clinical-stage biopharmaceutical company developing therapeutics based on nitrases for neurodegenerative and other diseases.

Investors · 6

Dementia Discovery Fundlisted by Dementia Discovery FundLondon

How we know: Dementia Discovery Fund's portfolio page · funding news · Not right? Tell us

Mission Biocapitallisted by Mission BiocapitalSan Francisco · $500K

How we know: Mission Biocapital's portfolio page · the VCSheet dataset · Not right? Tell us

Sofinnova Partnerslisted by Sofinnova PartnersParis · $540K – $27M

How we know: Sofinnova Partners's portfolio page · a partner's Signal profile · funding news · open dataset · 5k.vc investor directory · Not right? Tell us

SV Health Investorslisted by SV Health InvestorsLondon · $1M – $20M

How we know: SV Health Investors's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

AbbViereportedCambridge · $300K – $3M

How we know: a partner's Signal profile · open dataset · 5k.vc investor directory · Not right? Tell us

Mission Bay CapitalreportedSan Francisco

How we know: funding news · Not right? Tell us

Founder mafia

2 people who came through Nitrase Therapeutics went on to found or lead other companies.

Jonathan BehrMember Board of DirectorsFounded Tilos Therapeutics +1 Eric YuenChief Medical Officer (Consulting)Founded Spirovant

Related companies · 5

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Integrated Nanotherapeutics Inc.Integrated Nanotherapeutics develops lipid nanoparticle science and drug formulations for therapeutic applications. The company is led by scientists with over 100 years of collective expertise in preclinical research and drug development.

Nurix TherapeuticsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.

NeutrolisNeutrolis is a clinical-stage biotech developing first-in-class therapies that degrade neutrophil extracellular traps (NETs) to address the root cause of autoimmune and inflammatory diseases such as lupus and rheumatoid arthritis. Its approach targets the process of NETosis to treat these disorders without relying on immunosuppression.

DoximityDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.

Companies working in the same space as Nitrase Therapeutics.

In the news

Nitrase Therapeutics Announces the Appointment of Three Industry Veterans to Its Board of Directors | The Manila Timesmanilatimes.net · Aug 2026

Team - Nitrase Therapeuticsnitrasetx.com · Oct 2021

Frequently asked questions

What does Nitrase Therapeutics do?: Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration. Its lead program is an antibody targeting the pathogenic form of alpha-synuclein in Parkinson's disease, with a pipeline aimed at neurodegenerative, cancer, fibrotic, respiratory, and autoimmune diseases.
Who founded Nitrase Therapeutics?: Nitrase Therapeutics was founded by Irene Griswold-Prenner in 2018.
Who are Nitrase Therapeutics's investors?: Nitrase Therapeutics's investors include Dementia Discovery Fund, Mission Biocapital, Sofinnova Partners, SV Health Investors, AbbVie, Mission Bay Capital.